Epigenetic reprogramming sensitizes immunologically silent EBV(+) lymphomas to virus-directed immunotherapy

Despite advances in T-cell immunotherapy against Epstein-Barr virus (EBV)-infected lymphomas that express the full EBV latency III program, a critical barrier has been that most EBV(+) lymphomas express the latency I program, in which the single Epstein-Barr nuclear antigen (EBNA1) is produced. EBNA...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Dalton, Tanner, Doubrovina, Ekaterina, Pankov, Dmitry, Reynolds, Raymond, Scholze, Hanna, Selvakumar, Annamalai, Vizconde, Teresa, Savalia, Bhumesh, Dyomin, Vadim, Weigel, Christoph, Oakes, Christopher C., Alonso, Alicia, Elemento, Olivier, Pan, Heng, Phillip, Jude M., O’Reilly, Richard J., Gewurz, Benjamin E., Cesarman, Ethel, Giulino-Roth, Lisa
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7243148/
https://ncbi.nlm.nih.gov/pubmed/32157281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004126
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars